Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 13/20 | 0.56 |
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.56 |
| ▸ | HTR2C | P28335 | 4/20 | 0.54 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1550605 | 0.98 | HTR2C (0.56) | TLR7TLR9TLR8HTR2CQDPR | |
| SCHEMBL20281434 | 0.90 | TLR9 (0.48) | TLR7TLR9TLR8HTR2C | |
| SCHEMBL9277352 | 0.87 | IDO1 (0.50) | TLR7TLR9TLR8HTR2C | |
| Trifluoroacetic Acid SCHEMBL31227651 | 0.86 | TLR9 (0.47) | TLR7TLR9TLR8HTR2C | |
| SCHEMBL12093732 | 0.83 | IDO1 (0.45) | TLR7TLR9TLR8 | |
| SCHEMBL12093743 | 0.83 | IDO1 (0.45) | TLR7TLR9TLR8 | |
| SCHEMBL20031175 | 0.81 | UHRF1 (0.43) | TLR7TLR9TLR8 | |
| SCHEMBL22402327 | 0.81 | IDO1 (0.44) | TLR7TLR9TLR8 | |
| Cyanide SCHEMBL27912025 | 0.81 | IDO1 (0.47) | TLR7TLR9TLR8HTR2C | |
| SCHEMBL20281875 | 0.81 | HTR2A (0.48) | TLR7TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | TLR7 1930/4885TLR9 3789/4885TLR8 4093/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | TLR7 4408/4885TLR9 4681/4885TLR8 4411/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | TLR7 279/4885TLR9 494/4885TLR8 578/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | TLR7 1930/4885TLR9 3789/4885TLR8 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.